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Over the past seven years our knowledge of the systemic sclerosis (SSc) genetic 
component has considerably increased, mainly thanks to large genetic studies including 
genome wide association studies (GWASs) and Immunochip analysis (1-3). However, there 
is still a large portion of the SSc heritability that remains unexplained, as for most complex 
traits (4). One of the hypotheses proposed to explain the missing heritability for complex 
diseases involves rare and low-frequency variants. These types of genetic variations are not 
well covered by GWAS, which are mainly focused on common variants. However next-
generation sequencing technologies, like whole exome sequencing (WES), have rapidly 
overcome this issue. In this regard, Gao et al. performed for the first time WES on SSc and 
reported a novel gene, ATP8B4, as a risk factor for the disease (5). They suggested a missense 
rare variant (F436L [rs55687265]) as a potential causal variant for the association signal in 
ATP8B4. Therefore our aim was to further evaluate the reported signal of association taking 
advantage of our large SSc cohorts. 
 ATP8B4 rs55687265 rare variant was genotyped in six independent case-control sets 
of European ancestry reaching a total of 7,426 SSc patients and 13,087 healthy controls 
(Suppl. Table 1). All SSc patients fulfilled previously described classification criteria for the 
disease (3). First, we performed association analyses to test whether ATP8B4 rs55687265 
was associated with SSc susceptibility in each of the cohorts included in the present study 
(Supp Methods). A trend towards association was observed for the Spanish case-control set 
(Pvalue = 0.071, OR = 1.58) (Table 1). However, we did not observe any suggestive or 
significant signal of association for the remaining cohorts. We also observed opposite-
direction allelic effects across the different case-control sets. The meta-analysis combining 
all the sample sets, which was performed using an inverse variance fixed effects model, 
showed no significant association with the disease (Pmeta = 0.484, OR = 1.07) (Table 1 and 
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Supp Methods). Thus, according to our results, we did not find statistically significant 
differences of the ATP8B4 rs55687265*C allele frequency between the SSc patients and 
controls enrolled in the study. It is noteworthy that the impact of rare variants in the 
development of autoimmune diseases (ADs) remains an unanswered and controversial 
question (6). Moreover, high throughput DNA sequencing technologies, such as WES, are 
substantially affected by technical artifacts, which may lead to type I errors (7).  This issue 
becomes especially important when cases and controls have not been exactly sequenced in 
the same way, which leads to excessive false positive findings in detecting rare variant 
associations (7-9). The present study highlights the importance of validation of WES results 
with other sequencing methods as well as replication of the new associations in independent 
studies in order to detect actual disease-causing mutations.  
In conclusion, this study could not replicate the association of ATP8B4 rs55687265. 
However, the possible role of this gene cannot be discarded, since the present report did not 
attempt to evaluate whether other rare or common variants were associated with SSc 
susceptibility. 
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TABLE 
Table 1. Association analysis of ATP8B4 F436L variant in six independent cohorts and meta-
analysis. 
Cohort Minor/Major Cases/Controls 
MAF 
Cases 
MAF 
Controls P-value OR* [CI 95%] 
Spain C/G 2,056/2,718 0.008 0.005 0.071 1.58 [0.96-2.61] 
Germany C/G 909/486 0.019 0.022 0.613 0.87 [0.50-1.50] 
The Netherlands C/G 435/783 0.013 0.007 0.185 1.78 [0.75-4.20] 
Italy C/G 1,114/980 0.006 0.011 0.096 0.56 [0.28-1.12] 
UK  C/G 1,456/5,272 0.012 0.011 0.532 1.13 [0.77-1.67] 
USA C/G 1,456/2,848 0.015 0.015 0.991 1.00 [0.69-1.45] 
Meta-analysis** C/G 7,426/13,087     0.484 1.07 [0.88-1.31] 
*Odds ratio for the minor allele.  
**Q heterogeneity value = 0.17; I = 35.73 
CI, confidence interval; MAF, minor allele frequency; OR, odds ratio. 
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SUPPLEMENTARY MATERIAL 
Supplementary methods  
1. Genotyping methods 
The genotyping of ATP8B4 rs55687265 was performed with TaqMan SNP genotyping 
technology (assay ID: AHI1051) in a LightCycler® 480 Real-Time PCR System (Roche 
Applied Science, Mannheim, Germany). Genotyping call rate was > 95%. All the samples 
were genotyped by TaqMan assay, with the exception of the UK and USA control cohorts. 
For these two control sets, genotyping data were obtained from previously published studies 
(WTCCC and Lung Health Study, respectively) (1-2). 
2. Data analysis 
All the statistical analyses were carried out with PLINK v1.07 
(http://pngu.mgh.harvard.edu/purcell/plink/). Association test for the six cohorts were 
performed in each population by 2x2 contingency tables and χ2 test. P-values lower than 
0.05 were considered as statistically significant. The meta-analysis was performed with 
inverse-variance method under a fixed-effects model. Heterogeneity of the ORs across 
cohorts was assessed using Cochran’s Q test. None of the included control sets showed 
significant deviation from Hardy Weinberg Equilibrium (HWE) (HWE P-values < 0.01 were 
considered to show significant deviation from equilibrium). The statistical power of the 
combined analysis is shown in Supp. Table 2 and was calculated according to Power 
Calculator for Genetic Studies 2006 software under an additive model (3). 
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Supplementary tables 
Supp. Table 1. Study cohorts 
 
COHORT Patients with SSc Controls 
Spain 2,056 2,718 
Germany 909 486 
The Netherlands 435 783 
Italy  1,114 980 
UK  1,456 5,272 
USA 1,456 2,848 
TOTAL 7,426 13,087 
 
 
Supp. Table 2. Overall statistical power of the study for a statistical significance P-value 
= 0.05. 
 OR = 1.2 OR = 1.5 OR = 1.8 OR = 2.2 OR = 2.5 OR = 2.8 
rs55687265 43% 99% 100% 100% 100% 100% 
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Supplementary note 
Spanish Scleroderma Group 
Raquel Ríos and Jose Luis Callejas, Unidad de Enfermedades Sistémicas Autoinmunes, 
Department of Internal Medicine, Hospital Clínico Universitario San Cecilio, Granada; José 
Antonio Vargas Hitos, Department of Internal Medicine, Hospital Virgen de las Nieves, 
Granada; Rosa García Portales, Department of Rheumatology, Hospital Virgen de la 
Victoria, Málaga; María Teresa Camps, Department of Internal Medicine, Hospital Carlos 
Haya, Málaga; Antonio Fernández-Nebro, Department of Rheumatology, Hospital Carlos 
Haya, Málaga; María F. González-Escribano, Department of Immunology, Hospital 
Virgen del Rocío, Sevilla; Francisco José García-Hernández and Mª Jesús Castillo, 
Department of Internal Medicine, Hospital Virgen del Rocío, Sevilla; Mª Ángeles Aguirre 
and Inmaculada Gómez-Gracia, Department of Rheumatology, Hospital Reina 
Sofía/IMIBIC, Córdoba; Patricia Carreira, Department of Rheumatology. Hospital 
Universitario 12 de Octubre, Madrid; Benjamín Fernández-Gutiérrez and Luis 
Rodríguez-Rodríguez, Department of Rheumatology, Hospital Clínico San Carlos, Madrid; 
José Luis Andreu and Mónica Fernández de Castro, Department of Rheumatology, 
Hospital Puerta de Hierro Majadahonda, Madrid; Paloma García de la Peña, Department 
of Rheumatology, Hospital Madrid Norte Sanchinarro, Madrid; Francisco Javier López-
Longo and Lina Martínez, Department of Rheumatology, Hospital General Universitario 
Gregorio Marañón, Madrid; Vicente Fonollosa, Alfredo Guillén, Department of Internal 
Medicine, Hospital Valle de Hebrón, Barcelona; Gerard Espinosa, Department of Internal 
Medicine, Hospital Clinic, Barcelona; Iván Castellví, Department of Rheumatology, 
Hospital de la Santa Creu i Sant Pau, Barcelona; Anna Pros, Department of Rheumatology, 
Hospital Del Mar, Barcelona; Mónica Rodríguez Carballeira, Department of Internal 
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Medicine, Hospital Universitari Mútua Terrasa, Barcelona; Francisco Javier Narváez, 
Department of Rheumatology, Hospital Universitari de Bellvitge, Barcelona; Vera Ortiz-
Santamaría, Department of Rheumatology, Hospital General de Granollers, Granollers; 
Ana Belén Madroñero, Department of Internal Medicine, Hospital General San Jorge, 
Huesca. Miguel Ángel González-Gay, Epidemiology, Genetics and Atherosclerosis Research 
Group on Systemic Inflammatory Diseases, DIVAL, University of Cantabria, Santander; 
Bernardino Díaz and Luis Trapiella, Department of Internal Medicine, Hospital Central de 
Asturias, Oviedo; Mayka Freire and Adrián Sousa, Unidad de Trombosis y Vasculitis, 
Department of Internal Medicine, Hospital Xeral-Complexo Hospitalario Universitario de 
Vigo, Vigo; María Victoria Egurbide, Department of Internal Medicine, Hospital 
Universitario Cruces, Barakaldo; Patricia Fanlo Mateo, Department of Internal Medicine 
Hospital Virgen del Camino, Pamplona; Luis Sáez-Comet, Unidad de Enfermedades 
Autoinmunes Sistémicas, Department of Internal Medicine, Hospital Universitario Miguel 
Servet, Zaragoza; Federico Díaz and Vanesa Hernández, Department of Rheumatology, 
Hospital Universitario de Canarias, Tenerife; Emma Beltrán, Department of Rheumatology, 
Hospital General Universitario de Valencia, Valencia; Elena Grau, Department of 
Rheumatology, Hospital Universitario y Politécnico La Fe, Valencia; Juan José Alegre 
Sancho, Department of Rheumatology, Hospital del Doctor Peset, Valencia; Francisco J. 
Blanco García and Natividad Oreiro, Department of Rheumatology, INIBIC-Hospital 
Universitario A Coruña, La Coruña. 
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